Comparing surgical methods for endometrial cancer
Official title: Randomized Phase 3 Study of SELECTIVE SURGICAL STAGING Versus REFLEX Lymphadenectomy in Non-mappers Undergoing Sentinel Lymph Node Sampling for the Treatment of Endometrial Cancer
Run by University of Kentucky · NCT06677112 · Data updated 2026-11-12
This study is testing two different surgical methods for women with endometrial cancer to see which one helps them stay cancer-free longer after surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 625 (estimated) |
| Sponsor | University of Kentucky Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Lexington, Kentucky) |
| Status | Recruiting |
| Started | March 17, 2025 |
| Main results expected | January 2030 |
| Study ends | January 2030 |
| Registry record updated | November 13, 2025 |
| Trial ID | NCT06677112 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women with histologically confirmed endometrial cancer who are surgical candidates for complete hysterectomy and lymphadenectomy.
✕Probably not a fit
Patients with advanced disease or those who have undergone recent systemic chemotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to estimate recurrence-free survival rates in women with endometrial cancer by comparing selective surgical staging to sentinel node surgical staging. It will gather data to determine the most effective approach for evaluating lymph nodes during surgery. Participants will undergo complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy. The study will assess the outcomes of these surgical techniques to improve treatment strategies for endometrial cancer.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical techniques that enhance survival rates for patients with endometrial cancer.
How similar studies have gone: Other studies have shown promise in evaluating lymph node staging techniques in endometrial cancer, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy * Histologically or cytologically confirmed carcinoma of the endometrium confined to the uterine corpus * No clinical evidence of extra-uterine disease on pre-operative evaluation. Preoperative evaluation to rule-out extra-uterine disease may include a CT scan, MRI or ultrasound. Note: preoperative imaging is not mandatory for study enrollment. * Prior systemic chemotherapy is allowed so long as it was at least five years prior to study enrollment, and there is no evidence of disease after such therapy. Neoadjuvant chemotherapy for this endometrial cancer is not allowed. * Life expectancy (estimated survival) of at least 6 months. * AST(SGOT)/ALT(SGPT) \< 3.0X upper limit of normal * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * GOG Performance Status greater than 2 (Appendix II) * Uterine sarcoma * Clinical evidence of disease that extends beyond the uterus, including the presence of suspicious aortic or inguinal nodes on imaging or clinical exam * Previous vaginal, pelvic or abdominal irradiation * Chemotherapy or immunotherapy directed at the present disease * Previous pelvic lymphadenectomy or retroperitoneal surgery * Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen should be excluded * Known allergy to iodine or indocyanine green (ICG) tracer, or allergic reactions to compounds of similar chemical or biologic composition * Patients with uncontrolled intercurrent illness * Patients with psychiatric illness/social situations that would limit compliance with study requirements * Pregnant or lactating women. Women of child-bearing potential will be excluded if they have a positive serum/urine pregnancy test
Where it's running
-
University of Kentucky
Lexington, Kentucky, United States Recruiting
Study contacts
- Principal investigator: Rachel Miller, M.D. — University of Kentucky
- Study coordinator: Rachel Miller
- Email: raware00@uky.edu
- Phone: 859-323-2169
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized navigation to support rural and Black women with endometrial cancer
This pilot tests a tailored patient-navigation program to help rural and Black patients with endometrial cancer access care and services.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
-
Liquid biopsy screening for early endometrial cancer in regional China
A non-invasive blood test using cell-free DNA is being tested to see if it can detect early endometrial cancer and tell apart benign from malignant uterine lesions.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.